<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047980</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00079722</org_study_id>
    <secondary_id>2U54NS065705</secondary_id>
    <secondary_id>BVMC6209</secondary_id>
    <nct_id>NCT03047980</nct_id>
  </id_info>
  <brief_title>Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome</brief_title>
  <official_title>Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anne Comi, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Faneca 66 Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to gain a preliminary understanding of the safety of&#xD;
      sirolimus in Sturge-Weber syndrome (SWS) and determine best outcomes to be used to assess the&#xD;
      utility of sirolimus for the treatment of cognitive impairments related to Sturge-Weber&#xD;
      syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sirolimus will be administered as an adjunct to all current medications. The impact of&#xD;
      sirolimus upon cognitive functioning in Sturge-Weber syndrome is the primary outcome measure.&#xD;
      This outcome will be assessed using a panel of testing selected based upon extensive&#xD;
      experience in testing cognitive function in adults and children with SWS at the Kennedy&#xD;
      Krieger Sturge-Weber Center. Changes in a quantitative EEG before and after the trial,&#xD;
      Sturge-Weber syndrome clinical neuroscore, port-wine birthmark score, and the impact of&#xD;
      sirolimus upon seizures will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Actual">October 27, 2020</completion_date>
  <primary_completion_date type="Actual">June 4, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cognitive Function as Assessed by the National Institute of Health (NIH) Toolbox Cognitive Battery</measure>
    <time_frame>Baseline and at 6 months on the study drug</time_frame>
    <description>Change over six months in cognitive functioning in Sturge-Weber syndrome is the primary outcome measure. This outcome will be assessed using the NIH Toolbox Cognitive Battery, a panel of testing which includes the following measures:&#xD;
the Flanker Inhibitory Control and Attention Test (executive function and attention)&#xD;
the Dimensional Change Card Sort Test (executive function)&#xD;
Picture Sequence Memory Test (episodic memory)&#xD;
Oral Reasoning Recognition Test and Picture Vocabulary Test (language skills)&#xD;
Pattern Comparison Processing Speed Test (processing speed)&#xD;
List Sorting Working Memory Test (working memory)&#xD;
9-hole Peg Test (dexterity)&#xD;
Grip Strength Test (grip strength) and&#xD;
Patient-Reported Outcomes Measurement Information System (PROMIS) (self-report emotional functioning).&#xD;
These scores are rescaled to T scores (mean = 50, standard deviation (SD) = 10), referenced against the US population. Higher scores indicate better outcome. T scores only were analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Mean Power Asymmetry of the Occipital Alpha Frequency Band</measure>
    <time_frame>Baseline and at 6months on the study drug</time_frame>
    <description>Change in mean laterality score (by qEEG power analysis) was done comparing hemispheres and occipital lobes in the following frequency bands; delta, theta, alpha, beta, as previously described. As post-hoc analysis, baseline and follow-up qEEG of patients with and without stroke-like episodes were compared. Greater asymmetry with decreased power on the affected side is worse. We calculated a mean Laterality Score (LSb) for each band, averaged over 30 epochs and included channel pairs. Laterality Scores less than zero indicate lower power on the side ipsilateral to the port wine birthmark. In subjects who had a bilateral port wine birthmark, the side of maximal involvement was used (or the side of known involvement by MRI findings, where present).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sturge-Weber Syndrome Clinical Neuroscore</measure>
    <time_frame>Baseline and at 6 months on the study drug</time_frame>
    <description>Change in clinical neuroscore over the course of the study were measured. The neuroscore is comprised of frequency of seizures (0-4) , extent of hemiparesis (0-4), assessment of visual field cut (0-2) , and degree of cognitive functioning (0-5) with a minimum total score of 0 and a maximum total score of 15. Higher scores mean worsening of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Change in Sturge-Weber Syndrome Birthmark Score</measure>
    <time_frame>Visits at 2 weeks (baseline) and 28 weeks (study end)</time_frame>
    <description>Frontal and profile photograph will be taken under standardized conditions with scoring of the port-wine birthmark for percent of face covered, thickness of birthmark, and darkness of birthmark color.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Sturge-Weber Syndrome</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Low dose oral sirolimus</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Rapamycin</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ages 3 to 31 years of age, inclusive.&#xD;
&#xD;
          2. Cognitive impairment as defined by the following:&#xD;
&#xD;
             SWS cognitive neuroscore of ≥ 1&#xD;
&#xD;
          3. Ability to participate in direct neuropsychological and developmental testing.&#xD;
&#xD;
          4. English as primary language.&#xD;
&#xD;
          5. Stable anti-epileptic drugs (no changes in medications except dose for &gt;3 months).&#xD;
&#xD;
          6. Adequate renal function. GFR must be greater than 50 ml/min/m2 as determined by the&#xD;
             Schwartz Formula for children and MDRD for adults:&#xD;
             http://www.nkdep.nih.gov/professionals/gfr_calculators/index.htm&#xD;
&#xD;
          7. If female and of child bearing potential, documentation of a negative pregnancy test&#xD;
             prior to enrollment determined by a urine test is required. Sexually active&#xD;
             pre-menopausal female patients (and female partners of male patients) must use&#xD;
             adequate contraceptive measures, excluding estrogen containing contraceptives, while&#xD;
             on the study drug. Abstinence will be considered an adequate contraceptive measure.&#xD;
&#xD;
          8. INR ≤1.5 (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin&#xD;
             or on a stable dose of LMW heparin for &gt;2 weeks.)&#xD;
&#xD;
          9. Adequate liver function as shown by:&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5x ULN&#xD;
&#xD;
               -  ALT and AST ≤ 2.5x ULN&#xD;
&#xD;
         10. Written informed consent according to local guidelines. Local guidelines for subject&#xD;
             assent will also be followed.&#xD;
&#xD;
         11. Stable dose of medications affecting the cytochrome P 450 3A4 (CYP3A4) and p&#xD;
             glycoprotein (P gp) systems for at least 3 months prior to consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to sirolimus or other rapamycin analogues.&#xD;
&#xD;
          2. Patients with seizures secondary to metabolic, toxic, infectious or psychogenic&#xD;
             disorder, drug abuse or current seizures related to an acute medical illness.&#xD;
&#xD;
          3. Inability to keep follow-up appointments, maintain close contact with Principal&#xD;
             Investigators, and/or complete all necessary studies to maintain safety.&#xD;
&#xD;
          4. Patients in need of immediate major surgical intervention.&#xD;
&#xD;
          5. Concurrent severe and/or uncontrolled medical disease, which could compromise&#xD;
             participation in the pilot study (e.g. uncontrolled diabetes, uncontrolled&#xD;
             hypertension, severe infection, severe malnutrition, chronic liver or renal disease,&#xD;
             active upper GI tract ulceration, impaired or restrictive pulmonary function,&#xD;
             pneumonitis or pulmonary infiltrates).&#xD;
&#xD;
          6. Chronic treatment with systemic steroids or another immunosuppressive agent. Patients&#xD;
             with endocrine deficiencies are allowed to receive physiologic or stress doses of&#xD;
             steroids if necessary. Inhaled steroids are allowed.&#xD;
&#xD;
          7. Known history of HIV seropositivity or known immunodeficiency. Testing is not required&#xD;
             unless a condition is suspected.&#xD;
&#xD;
          8. Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of sirolimus (e.g. ulcerative disease, uncontrolled&#xD;
             nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection). A&#xD;
             gastric tube or nasogastric tube is allowed.&#xD;
&#xD;
          9. Patients with an active, bleeding diathesis.&#xD;
&#xD;
         10. Patients with uncontrolled hyperlipidemia: fasting serum cholesterol &gt; 300 mg/dL AND&#xD;
             fasting triglycerides &gt; 2.5 x ULN.&#xD;
&#xD;
         11. Patients who have had a major surgery or significant traumatic injury within four&#xD;
             weeks of study entry. Patients who have not recovered from the side effects of any&#xD;
             major surgery (defined as requiring general anesthesia) or patients that may require&#xD;
             major surgery during the course of the pilot study.&#xD;
&#xD;
         12. Patients with a prior history of organ transplant.&#xD;
&#xD;
         13. Patients who have received live attenuated vaccines within one week of start of&#xD;
             sirolimus and during the pilot study.&#xD;
&#xD;
         14. Patients who have a history of malignancy.&#xD;
&#xD;
         15. Patients who are currently part of or have participated in any clinical investigation&#xD;
             with an investigational drug within one month prior to enrollment.&#xD;
&#xD;
         16. Patients being treated with felbamate, unless treatment has been continuous for ≥ one&#xD;
             year.&#xD;
&#xD;
         17. Patients currently receiving anticancer therapies or who have received anticancer&#xD;
             therapies within four weeks of study entry (including chemotherapy, radiation therapy,&#xD;
             antibody based therapy, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>31 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne M Comi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kennedykrieger.org/patient-care/patient-care-centers/sturge-weber-center</url>
    <description>Hunter Nelson Sturge-Weber Center Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <results_first_submitted>August 24, 2021</results_first_submitted>
  <results_first_submitted_qc>September 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2021</results_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</investigator_affiliation>
    <investigator_full_name>Anne Comi, MD</investigator_full_name>
    <investigator_title>Principal Investigator, Director Sturge-Weber Center, Kennedy Krieger Institute, Professor Johns Hopkins University School of Medicine</investigator_title>
  </responsible_party>
  <keyword>SWS</keyword>
  <keyword>Cognitive impairment</keyword>
  <keyword>sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sturge-Weber Syndrome</mesh_term>
    <mesh_term>Brain Stem Infarctions</mesh_term>
    <mesh_term>Klippel-Trenaunay-Weber Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03047980/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All enrolled participants will receive oral sirolimus.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus</title>
          <description>All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.&#xD;
Sirolimus: Low dose oral sirolimus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sirolimus</title>
          <description>All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.&#xD;
Sirolimus: Low dose oral sirolimus</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.58" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cognitive Function as Assessed by the National Institute of Health (NIH) Toolbox Cognitive Battery</title>
        <description>Change over six months in cognitive functioning in Sturge-Weber syndrome is the primary outcome measure. This outcome will be assessed using the NIH Toolbox Cognitive Battery, a panel of testing which includes the following measures:&#xD;
the Flanker Inhibitory Control and Attention Test (executive function and attention)&#xD;
the Dimensional Change Card Sort Test (executive function)&#xD;
Picture Sequence Memory Test (episodic memory)&#xD;
Oral Reasoning Recognition Test and Picture Vocabulary Test (language skills)&#xD;
Pattern Comparison Processing Speed Test (processing speed)&#xD;
List Sorting Working Memory Test (working memory)&#xD;
9-hole Peg Test (dexterity)&#xD;
Grip Strength Test (grip strength) and&#xD;
Patient-Reported Outcomes Measurement Information System (PROMIS) (self-report emotional functioning).&#xD;
These scores are rescaled to T scores (mean = 50, standard deviation (SD) = 10), referenced against the US population. Higher scores indicate better outcome. T scores only were analyzed.</description>
        <time_frame>Baseline and at 6 months on the study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.&#xD;
Sirolimus: Low dose oral sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Function as Assessed by the National Institute of Health (NIH) Toolbox Cognitive Battery</title>
          <description>Change over six months in cognitive functioning in Sturge-Weber syndrome is the primary outcome measure. This outcome will be assessed using the NIH Toolbox Cognitive Battery, a panel of testing which includes the following measures:&#xD;
the Flanker Inhibitory Control and Attention Test (executive function and attention)&#xD;
the Dimensional Change Card Sort Test (executive function)&#xD;
Picture Sequence Memory Test (episodic memory)&#xD;
Oral Reasoning Recognition Test and Picture Vocabulary Test (language skills)&#xD;
Pattern Comparison Processing Speed Test (processing speed)&#xD;
List Sorting Working Memory Test (working memory)&#xD;
9-hole Peg Test (dexterity)&#xD;
Grip Strength Test (grip strength) and&#xD;
Patient-Reported Outcomes Measurement Information System (PROMIS) (self-report emotional functioning).&#xD;
These scores are rescaled to T scores (mean = 50, standard deviation (SD) = 10), referenced against the US population. Higher scores indicate better outcome. T scores only were analyzed.</description>
          <units>T score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>National Institute of Health Toolbox Vocabulary Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Toolbox Vocabulary Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Toolbox Attention Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Toolbox Attention Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Toolbox Working Memory Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Toolbox Working Memory Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Toolbox Executive Function Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Toolbox Executive Function Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Processing Speed Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Processing Speed Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Toolbox Sequential Memory Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Toolbox Sequential Memory Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Toolbox Recognition Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National Institute of Health Toolbox Recognition Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System Pain (PROMIS) Interference Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Interference Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System (PROMIS) Peer Relations Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient-Reported Outcomes Measurement Information System (PROMIS) Peer Relations Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grip Strength Dominant Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grip Strength Dominant Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grip Strength Non-Dominant Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grip Strength Non-Dominant Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dexterity Dominant Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dexterity Dominant Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dexterity Non-Dominant Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dexterity Non-Dominant Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Mean Power Asymmetry of the Occipital Alpha Frequency Band</title>
        <description>Change in mean laterality score (by qEEG power analysis) was done comparing hemispheres and occipital lobes in the following frequency bands; delta, theta, alpha, beta, as previously described. As post-hoc analysis, baseline and follow-up qEEG of patients with and without stroke-like episodes were compared. Greater asymmetry with decreased power on the affected side is worse. We calculated a mean Laterality Score (LSb) for each band, averaged over 30 epochs and included channel pairs. Laterality Scores less than zero indicate lower power on the side ipsilateral to the port wine birthmark. In subjects who had a bilateral port wine birthmark, the side of maximal involvement was used (or the side of known involvement by MRI findings, where present).</description>
        <time_frame>Baseline and at 6months on the study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.&#xD;
Sirolimus: Low dose oral sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Mean Power Asymmetry of the Occipital Alpha Frequency Band</title>
          <description>Change in mean laterality score (by qEEG power analysis) was done comparing hemispheres and occipital lobes in the following frequency bands; delta, theta, alpha, beta, as previously described. As post-hoc analysis, baseline and follow-up qEEG of patients with and without stroke-like episodes were compared. Greater asymmetry with decreased power on the affected side is worse. We calculated a mean Laterality Score (LSb) for each band, averaged over 30 epochs and included channel pairs. Laterality Scores less than zero indicate lower power on the side ipsilateral to the port wine birthmark. In subjects who had a bilateral port wine birthmark, the side of maximal involvement was used (or the side of known involvement by MRI findings, where present).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with Stroke-Like Episodes Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.686" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Stroke-Like Episodes Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.426" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without Stroke-like episodes Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.167" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without stroke-line episodes follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.247" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sturge-Weber Syndrome Clinical Neuroscore</title>
        <description>Change in clinical neuroscore over the course of the study were measured. The neuroscore is comprised of frequency of seizures (0-4) , extent of hemiparesis (0-4), assessment of visual field cut (0-2) , and degree of cognitive functioning (0-5) with a minimum total score of 0 and a maximum total score of 15. Higher scores mean worsening of symptoms.</description>
        <time_frame>Baseline and at 6 months on the study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.&#xD;
Sirolimus: Low dose oral sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sturge-Weber Syndrome Clinical Neuroscore</title>
          <description>Change in clinical neuroscore over the course of the study were measured. The neuroscore is comprised of frequency of seizures (0-4) , extent of hemiparesis (0-4), assessment of visual field cut (0-2) , and degree of cognitive functioning (0-5) with a minimum total score of 0 and a maximum total score of 15. Higher scores mean worsening of symptoms.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite Score Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite Score Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizure Score Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizure Score Follow-Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemiparesis Score Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemiparesis Score Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Field Cut Score Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Field Cut Score Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Function Score Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Function Score Follow-Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Change in Sturge-Weber Syndrome Birthmark Score</title>
        <description>Frontal and profile photograph will be taken under standardized conditions with scoring of the port-wine birthmark for percent of face covered, thickness of birthmark, and darkness of birthmark color.</description>
        <time_frame>Visits at 2 weeks (baseline) and 28 weeks (study end)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.&#xD;
Sirolimus: Low dose oral sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Change in Sturge-Weber Syndrome Birthmark Score</title>
          <description>Frontal and profile photograph will be taken under standardized conditions with scoring of the port-wine birthmark for percent of face covered, thickness of birthmark, and darkness of birthmark color.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved Port-Wine Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change Port-Wine Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened Port-Wine Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Port-Wine Birthmark</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>The Rare Diseases Clinical Research Network defines an adverse event as &quot;...an unfavorable and unintended sign, symptom or disease associated with a participants' participation in a Rare Disease Clinical Research Network Study.&quot; The three types of adverse events are serious adverse events, unexpected adverse events and expected adverse events. This classification is using Common Terminology Criteria for Adverse Events developed and maintained by CTEP at National Cancer Institute.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sirolimus</title>
          <description>All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.&#xD;
Sirolimus: Low dose oral sirolimus</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Subject's final visit labs showed asymptomatic anemia with hemoglobin of 7.3. Patient had dark stools previously, making a GI bleed the likely source. She was off the study drug for 2 weeks prior so this is probably not related to the study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Subject had a bad migraine with visual aura and was hospitalized on 9/27/2017. He was treated in the ER and hospitalized. Subject has a history of these events prior to going on study drug. This was deemed probably not related to the study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Subject developed a headache with vomiting and tingling/numbness on the left side. She experienced 2 brief focal seizures while in ER. This was probably not related to the study drug as the patient has a history of this event prior to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased Alanine Aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Increased aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cholesterol High</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Decreased HDL Cholesterol</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Personality Change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Behavioral Issues/ Aggression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Urine Labs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Ulceration in Mouth</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Assistant</name_or_title>
      <organization>Kennedy Krieger Institute</organization>
      <phone>443-923-9569 ext 3-9569</phone>
      <email>vedmurthyp@kennedykrieger.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

